TheraCoat is a clinical stage specialty pharmaceutical company focused on innovative drug delivery solutions for the treatment of intra-cavital diseases, focusing initially in the urinary tract. TheraCoat technology enables control on the pharmacokinetics of off-the-shelf drugs resulting in an optimized Therapeutic Index without changing the drug molecular structure.
TheraCoat sustained release treatments enable controlled and longer exposure of bladder tissue to medications (such as chemotherapy) as compared to standard intravesical instillations. Pre-clinical results have shown over ten-fold higher drug concentration in the bladder tissue and significantly lower levels in the plasma compared to standard instillation, indicating a potential for significantly higher efficacy and better safety.
TheraCoat core capabilities are based on using a family of proprietary reverse thermal-gelation hydrogels that have ideal properties for deployment of medications into the bladder.
TheraCoat has been granted CE Mark clearance as a Medical Device.
TheraCoat is currently focused on local treatments of bladder diseases –non-muscle-invasive or superficial bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC), interstitial cystitis (IC) and overactive bladder (OAB) – treatments that together address over 100 million patients worldwide.